Global Secukinumab Market - Industry Trends and Forecast to 2029

Market Analysis and Insights Global Secukinumab Market

Secukinumab market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 5.80% in the above mentioned forecast period.

Secukinumab injection belongs to the monoclonal antibody class of drugs. It works by inhibiting the actions of certain cells in the body that cause psoriasis symptoms. It's an antibody that binds to interleukin 17A (IL-17A), an immune-stimulating molecule produced by cells in the body. This drug is administered as an injection under the skin, generally in the upper arms, stomach, or thighs. Cosentyx is the brand name for secukinumab. Side effects of this medication are rash, hives, difficulty breathing, feeling faint, swelling, chest tightness, itching and hoarseness.

The rise in the incidences of ankylosing spondylitis and psoriatic arthritis globally is the major factor driving the market’s growth rate. Additionally, rising healthcare expenditure is the market driver influencing the growth rate of secukinumab market. Furthermore, increasing prevalence of dermatological disorders and upsurge in the number of clinical trial studies are the factors that will expand the secukinumab market. Other factors including rise in the growing government initiatives and rising awareness will positively impact the market growth rate. Another significant factor that will cushion the growth of secukinumab market is the increase in demand from various end-use industries. Also, rise in the level of disposable income and rapid urbanization will escalate the market growth rate for the mention forecast period mentioned above. Changing lifestyle and rising inclination towards smoking and alcohol consumption will drive the growth of secukinumab market for the above mentioned forecast period.

Moreover, the rise in the research and development activities and emerging new markets will provide beneficial opportunities for the secukinumab market in the forecast period of 2022-2029. Additionally, continuous clinical trials and the improving healthcare infrastructure will act as major markets drivers that will create new opportunities for the markets growth rate.

However, high cost associated with product will impede the market’s growth rate. Also, side effects such as rash, hives, difficulty breathing, feeling faint, swelling, chest tightness, itching and hoarseness will hamper the secukinumab market’s growth. Lack of awareness will further challenge the secukinumab market in the forecast period mentioned above.

This secukinumab market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the secukinumab market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Secukinumab Market Scope and Market Size

The secukinumab market is segmented on the basis of product type, drug class, demographic, application, dosage form, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of product type, the secukinumab market is segmented into sensoready pen, prefilled syringe, and powder for solution.
• On the basis of drug class, the secukinumab market is segmented into interleukin inhibitors, and others.
• On the basis of demographic, the secukinumab market is segmented into adult, and pediatric.
• On the basis of application, the secukinumab market is segmented into ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and others.
• On the basis of dosage form, the secukinumab market is segmented into subcutaneous solution and others. The segment of subcutaneous solution is further sub-segmented into 150 mg/mL and 75 mg/0.5 mL.
• On the basis of end-users, the secukinumab market is segmented into clinic, hospital and others.

The secukinumab market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Secukinumab Market Country Level Analysis

Secukinumab market is analyzed and market size information is provided by the country, product type, drug class, demographic, application, dosage form, end-users and distribution channel as referenced above.

The countries covered in the secukinumab market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the secukinumab market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing research and development activities and rising government support in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Secukinumab market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Secukinumab Market Share Analysis

Secukinumab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to secukinumab market research.

Some of the major player operating in the secukinumab market is Novartis AG, among others.

SKU-67672